<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/259282-aerosol-suspension-formulations-containing-tg-227-ea-or-tg-134-a-as-a-propellant by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 02:35:29 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 259282:&quot;AEROSOL SUSPENSION FORMULATIONS CONTAINING TG 227 EA OR TG 134 A AS A PROPELLANT&quot;</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">&quot;AEROSOL SUSPENSION FORMULATIONS CONTAINING TG 227 EA OR TG 134 A AS A PROPELLANT&quot;</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>The invention relates to propellant formulations containing at least one suspended active ingredient which contains chemically bound water, water, and the propellant TO 227 or TG 134 a.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>AEROSOL SUSPENSION FORMULATIONS CONTAINING TG 227 EA OR<br>
TG 134 A AS A PROPELLANT<br>
The invention relates to pressurised gas preparations for metered-dose aerosols wherein a pharmaceutical composition is formulated as a suspension in TG 227 ea (1,1,1,2,3,3,3-heptafluoropropane) or TG 134 a (1,1,1,2-tetrafluoroethane) as propellant, and the use thereof for preparing a pharmaceutical composition. It preferably relates to an inhalable aerosol.<br>
Prior art<br>
Ever since the public discussions on the ozone-damaging potential of certain chlorofluorocarbons there has been intensive work in the field of alternative propellants for pharmaceutical metered-dose aerosols. It has been known since the early 1990s that the propellant gases TG 227 ea or TG 134 a may be used as alternative propellant gases for aerosols.<br>
It has now been found that, surprisingly, propellant gas formulations with suspended particles of active substance and TG 227 ea or TG 134 a as propellant can be stabilised if the propellant gas or propellant gas mixture contains a certain amount of water.<br>
Detailed description of the invention<br>
For the propellant formulations according to the invention TG 227 ea and/or TG 134 a are used as propellant gases, optionally in admixture with one or more other propellant gases, preferably selected from among propane, butane, pentane, dimethylether, CHC1F2, CH2F2, CF3CH3, isobutane, isopentane and neopentane.<br>
Preferred suspensions according to the invention are those which contain as propellant gas<br>
only TG 227 ea or only TG 134 a.<br>
If a mixture of the propellant gases TG 227 ea and TG 134a is used in the suspension<br>
formulations according to the invention, the proportions by weight in which these two<br>
propellant gas components may be used may be freely variable, although TG 227 ea must be<br>
present.<br>
In mixtures with one or more other propellant gases, selected from among propane, butane,<br>
pentane, dimethylether, CHCIF2, CH2F2, CT^CHb, isobutane, isopentane and neopentane, the<br>
proportion of this other propellant gas component is preferably less than 60 %, preferably<br>
below 40% and most preferably less than 30%.<br><br>
The active substances used are preferably active substances which incorporate or bind one or more water molecules in their particle structure. The water is not only physically mixed with the particles of active substance. Preferably the particles of active substance are crystals and the water is water of crystallisation or complex-bound water or water which is otherwise chemically bound, e.g. hydrates. This form of water incorporation is hereinafter also referred to as chemically bound water. In these cases the water generally also affects the crystalline structure of the active substance molecule.<br>
Compounds which are effective by inhalation are preferably used, with the result that the suspension formulations according to the invention are preferably intended for inhalation.<br>
Particularly preferred in this context are pharmaceutical compositions selected from among the anticholinergics, betamimetics, steroids, phosphodiesterase IV inhibitors, LTD4-antagonists and EGFR-kinase inhibitors, antiallergics, ergot alkaloid derivatives, triptanes, CGRP antagonists, phosphodiesterase-V inhibitors, and combinations of active substances of this kind, e.g. betamimetics plus anticholinergics or betamimetica plus antiallergics. In the case of combinations at least one of the active substances contains chemically bound water. Anticholinergic-eontainmg active substances are preferably used, as monopreparations or in the form of combined preparations.<br>
The following are specific examples of the active ingredients or the salts thereof:<br>
Anticholinergics to be used are preferably selected from among tiotropium bromide, oxitropium bromide, flulropium bromide, ipratropium bromide, glycopyrronium salts, Irospium chloride, tolterodine, tropenol 2,2-diphenylpropionate methobromide, scopine 2,2-diphenylpropionate methobromide, scopine 2-fluoro-2,2-diphenylacetate-methobromide, tropenol 2-fluoro-2,2-diphenylacetate-methobromide, tropenol 3,3',4,4'-tetrafluorobenzilate methobromide, scopine 3,3',4,4'-tetrafluorobenzilate methobromide, tropenol 4,4'-difluorobenzilate methobromide, scopine 4,4'-difluorobenzilate methobromide, tropenol 3,3'-difluorobenzilate methobromide, scopine 3,3'-difluorobenzilate methobromide, tropenol 9-hydroxy-fIuorene-9-carboxylate methobromide, tropenol 9-fluoro-fluorene-9-carboxylate methobromide, scopine 9-hydroxy-fluorene-9-carboxylate methobromide, scopine 9-fluoro-lluorene-9-carboxylate methobromide, tropenol 9-methyl-fluorene-9-carboxylate methobromide, scopine 9-methyl-rluorene-9-carboxylate methobromide, cyclopropyltropine<br><br>
benzilate methobromide, 2,2-diphenylpropionate cyclopropyltropine methobromide, cyclopropyllropine 9-hydroxy-xanthene-9-carboxylate methobromide, cyclopropyltropine 9-methyl-fluorene-9-carboxylate methobromide, cyclopropyltropine 9-methyl-xanthene-9-carboxylate methobromide, cyclopropyltropine 9-hydroxy-fluorene-9-carboxylate methobromide, methyl cyclopropyltropine 4,4'-diiluorobenzilate methobromide, tropenol 9-hydroxy-xanthene-9-carboxylate methobromide, scopine 9-hydroxy-xanthene-9-carboxylate methobromide, tropenol 9-methyl-xanthene-9-carboxylate methobromide, scopine 9-methyl-xanthene-9-carboxylate methobromide, tropenol 9-ethyl-xanthene-9-carboxylate methobromide, tropenol 9-difluoromethyl-xanthene-9-carboxylate methobromide and scopine 9-hydroxymethyl-xanthene~9-earboxylate methobromide, optionally in the form of the racemates, enantiomers or diastereomers thereof and optionally in the form of the solvates and/or hydrates thereof.<br>
Betamimetics which may be used are preferably selected from among albuterol, bambuterol, bitolterol, broxaterol, carbuterol, clenbuterol, fenoterol, formoterol, hexoprenaline, ibuterol, isoetharine, isoprenaline, levosalbutamol, mabuterol, meluadrine, metaproterenol, orciprenaline, pirbuterol, procaterol, reproterol, rimiterol, ritodrine, salmeterol, salmefamol, soterenot, sulphonterol, tiaramide, terbutaline, tolubuterol, CHF-1035, HOKU-81, KUL-1248, l-(4-{6-[2-hydroxy-2-(4-hydroxy-3-hydroxymethyl-phenyl)-ethylamino]-hexyloxy}-butyl)-benzenesulphonamide, 5-[2-(5,6-diethyl-indan-2-ylamino)-l-hydroxy-ethyl]-8-hydroxy-l//-quinolin-2-one, 4~hydroxy~7-[2-{[2-{[3-(2-phenylethoxy)propyl]sulphonyl}ethyl]-amino}ethyl]-2(3H)-benzothiazolone, l-(2-fluoro-4-hydroxyphenyl)-2-[4-(l-benzimidazolyl)-2-methyl-2-butylamino]ethanol, l-[3-(4-methoxybenzyl-amino)~4-hydroxyphenyl]-2-[4-(l-benzimidazolyl)-2-methyl-2-butylamino]ethanol, l-[2H-5-hydroxy-3-oxo-4H-l,4-benzoxazin-8-yl]-2-[3-(4-N,N-dimethylaminophenyl)-2-methyl-2-propyIamino]ethanol, 1-[2H-5-hydroxy-3-oxo-4H- l,4-benzoxazin-8-yl]-2-[3-(4-methoxyphenyl)-2-methyl-2-propylaminojethanol, l-[211-5-hydroxy-3-oxo-4H-l,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylaminojethanol, l-[2H-5-hydroxy-3-oxo-4H-l,4-benzoxazin-8-yl]-2-{4-[3-(4-methoxyphenyI)-l,2,4-triazol-3-yl]-2-methyl-2-butylamino}ethanol, 5-hydroxy-8-(l-hydroxy-2-isopropylaminobutyl)-2H-l,4-benzoxazin-3-(4H)-one, I -(4-amino-3-chloro-5-trifluoromethylphenyl)-2-tert.-butylamino)ethanol and l-(4-ethoxycarbonyIamino-3-cyano-5-fluorophenyl)-2-(tert.-butylamino)ethanol, optionally in the form of the racemates, enantiomers or diastereomers thereof and optionally in the form of the pharmacologically acceptable acid addition salts, solvates and/or hydrates thereof.<br>
Steroids which may be used are preferably selected from among prednisolone, prednisone, butixocortpropionate, RPR-106541, fmnisolide, beclomethasone, triamcinolone, budesonide,<br><br>
fluticasone, mometusone, ciclesonidc, rofleponide, ST-126, dexamethasone, (S)-fluoromethyl 6a,9cx-difluoro-l 7a-[(2-furanylcarbonyl)oxy]-l l|3-hydroxy-16a-methyl-3-oxo-androsta-l,4-diene-17j3-carbothionate, (S)-(2-oxo-tetrahydro-furan-3S-yl) 6a,9a-difluoro-l l[3-hydroxy-16a-methyl-3-oxo-17a-propionyloxy-androsta-1,4-diene-17p-carbothionate and etiprednol-dichloroacetate (BNP-166), optionally in the form of the racemates, enantiomers or diastereomers thereof and optionally in the form of the salts and derivatives thereof, the solvates and/or hydrates thereof.<br>
PDE IV inhibitors which may be used are preferably selected from among enprofyllin, theophyllin, rollumilast, ariflo (cilomilast), CP-325,366, BY343, D-4396 (Sch-351591), AWD-12-281 (GW-842470), N-(3,5-dichloro-l-oxo-pyridin-4-yl)-4-difluoromethoxy-3-cyclopropylmethoxybenzamide, NCS-613, pumafentine, (-)p-[(4aR*,106S*)-9-ethoxy-1,2,3,4,4a, 1 Ob~hexahydro-8-rnethoxy-2-methylbenzo[s] [ 1,6]naphthyridin-6-yl]-N,N-diisopropylbenzamide, (R)-(+)-l-(4-bromobenzyl)-4-[(3-cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidone, 3-(cyclopenty!oxy-4-methoxyphenyl)-1 ~(4-N'-[N-2-cyano-S-methyl-isothioureido]benzyl)-2-pyrrolidone, cis[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexane-l -carboxylic acid], 2-carbomethoxy-4-cyano-4-(3-cyclopropylmethoxy-4-ditluoromethoxyphenyl)cyclohexan-l-one, cis[4-cyano-4-(3-cyclopropylmethoxy-4-chnuoromethoxyphenyl)cyclohexan-l-ol], (R)-(+)-ethyl[4-(3-cyclopentyloxy-4-methoxyphenyl)pyrrolidin-2-ylidene]acetate, (S)-(-)-ethyl[4-(3-cyclopentyloxy-4-methoxyphenyl)pyiTolidin-2-ylidene]acetate, CDP840, Bay-198004, D-4418, PD-168787, T-440, T-2585, arofyllin, atizoram, V-11294A, Cl-1018, CDC-801, CDC-3052, D-22888, YM-58997, Z-15370, 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-thienyl)-9//-pyrazolo[3,4-c]-l,2,4-triazolo[4,3-a]pyridme and 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(/erf-butyl)-9//-pyrazolo[3,4-c]-l,2,4-triazolo[4,3-a]pyridine, optionally in the form of the racemates, enantiomers or diastereomers thereof and optionally in the form of the pharmacologically acceptable acid addition salts, solvates and/or hydrates thereof.<br>
LTD4-antagonists which may be used are preferably selected from among montelukast, l-(((R)-(3-(2-(6,7-dinuoro-2-quinolinyl)ethenyl)phenyl)-3-(2-(2-hydroxy-2-propyl)phenyl)thio)methylcyclopropane-acetic acid, l-(((l(R)-3(3-(2-(2,3-dichlorothieno[3,2-b]pyridin-5-yI)-(E)-ethenyl)phenyl)-3-(2-(l-hydroxy-l-methylethyl)phenyl)propyl)thio)-methyl)cyclopropane-acetie acid, pranlukast, zafirlukast, [2-[[2-(4-tert-butyl-2-thiazolyl)-5-benzofuranyl'oxymethyljphenyl]acetic acid, MCC-847 (ZD-3523), MN-001, MEN-91507 (LM-1507), VUF-5078, \ UF-K-8707 and L-733321, optionally in the form of the racemates, enantiomers or diastereomers thereof, optionally in the form of the pharmacologically<br><br>
acceptable acid addition salts thereof and optionally in the form of the salts and derivatives thereof, the solvates and/or hydrates thereof.<br>
EGFR-kinase inhibitors which may be used are preferably selected from among cetuximab, trastuzumab, ABX-EGF, Mab ICR-62, 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(morpholin-4-yl)-l-oxo-2-buten-l-yl]amino}-7-cyclopropylmethoxy-quinazoline, 4-[(R)-(l-phenyl-ethyl)amino]-6-{[4-(morpholin-4-yl)-l-oxo-2-buten-l-yl]amino}-7-cyclopentyloxy-quinazoline, 4-|(3-chloro-4-lluoro-phenyl)amino]-6-{[4-((R)-6-methyl-2-oxo-morpholin-4-yl)-l-oxo-2-buten-l-yl|amino}-7-[(S)-(tetrahydrofuran-3-yl)oxy]-quinazoline, 4-[(3-chloro-4-nuoro-phenyl)amino]-6-j2-((S)-6-methyl-2-oxo-morpholin-4-yl)-ethoxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-nuoropheny])amino]-6-({4-[N-(2-methoxy-ethyl)-N-methyl-amino |-1 -oxo-2-buten-1 -yl} amino)-7-cyclopropylmethoxy-quinazoline, 4-[(R)-( 1 -phenyl-ethyl)amino]-6-({4-[N-(tetrahydropyran-4-yl)-N-methyl-amino]-l-oxo-2-buten-l-yl}amino)-7-cyclopropylmethoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-(2-methoxy-ethyl)-N-methyl-amino]-l-oxo-2-buten-l-yl}amino)-7-cyclopentyloxy-quinazoline, 4-f(3-chloro-4-fluorophenyl)aminoJ-6-{[4-(N,N-dimethylamino)-l -oxo-2-buten- l-yl]amino}-7-f(R)-(tetrahydrofiiran-2-yl)methoxy]-quinazoline, 4-[(3-ethynyl-phenyl)amino]-6,7-bis-(2-methoxy-ethoxy)-quina/oline, 4-[(R)-(l-phenyl-ethyl)amino]-6-(4-hydroxy-phenyl)-7H-pyrrolo[2,3-djpyrimidine, 3-cyano-4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimelhylamino)-!-oxo-2-buten-l-yl]amino}-7-ethoxy-quinoline, 4-[(R)-(l-phenyl-ethyl)amino]-6-{[4-((R)-6-methyl-2-oxo-morpholin-4-yl)-l -oxo-2-buten- l-yl]amino} -7-methoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(morpholin-4-yl)-l-oxo-2-buten-1 -yl]amino}-7-[(tetrahydrofuran-2-yl)methoxy]-quinazoline, 4-[(3-ethynyl-phenyl)amino]-6-{[4-(5,5 -dirnethyl-2-oxo-morpholin-4-yl)-l -oxo-2-buten- l-yl]amino}-quinazoline, 4-[(3-chloro--4-fluoro-phenyl)amino]-6-{2-[4-(2-oxo-morpholin-4-yl)-piperidin-l-ylJ-ethoxy}-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-amino-cyclohexan-l-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-methanesulphonylamino-cyclohexan-l-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-3-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{ l-[(morpholin-4-y])carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazolme, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(piperidin-3-yloxy)-7-methoxy-quina/oline, 4-f('3-chloro-4-fluoro-phenyl)aminoJ-6-[l-(2-acetylamino-ethyl)-piperidin-4-yloxyj-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-ethoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{trans-4-[(morpholin-4-yl)carhonylamHK)]-cyclohexan-l-yloxy!-7-methoxy-quinazoline,<br>
4-|(3-chloro-4-nuoro-phenyl)amino]-6- }l-[(piperidin-l-yl)carbonylJ-piperidin-4-yloxy}-7-rnethoxy-quinazoline, 4-|(3-chloro-4-tluoro-phenyl)amino]-6-(eis-4-{N-[(morpholin-4-<br><br>
yl)carbonyl]-N-rnethyl-aniino}-cyclohexan-l-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-ethansulphonylamino-cyclohexan-l-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)aminoJ-6-(l-methanesulphonyl-piperidin-4-yloxy)-7-(2-methoxy-ethoxy)-quinazoline, 4-[(3-chloro-4-iluoro-phenyl)amino]-6-[l-(2-methoxy-acctyl)-piperidin-4-yloxy]-7-(2-methoxy-ethoxy)-quinazoline, 4-[(3-ethynyl-phenyl)aminoj-6-(tetrahydropyran-4-yloxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4- {N-[(piperidin-1 -yl icarbonyl ]-N-methyl-amino} -cyclohexan-1 -yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{cis-4-[(morpholin-4-yl)carbonylamino]-cyclohexan-1-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{l-[2-(2-oxopyiTolidin-l-yl)ethyl]-piperidin-4-yloxy}-7-methoxy-quinazoline, 4-[(3-ethynyl-pheny])amino)-6-(l-acetyl-piperidin-4-yloxy)-7-rnethoxy-quinazoline, 4-[(3-ethynyl-pheny])amino]-6-(l-methyl-piperidin-4-yloxy)-7-methoxy-quinazoline, 4-[(3-ethynyl-phenyl)aminoj-6-(l-niethanesulphonyl-piperidin-4-yloxy)-7-methoxy-quinazoline, 4-[(3-chk&gt;ro-4-fluoro-phenyl)aminoJ-6-(l-niethyl-piperidin-4-yloxy)-7(2-methoxy-ethoxy)-quinazoline, 4-[(3-ethynyl-phenyl)amino]-6-{l-[(morpholin-4-yl)carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1 -[(N-methyl-N-2-inethoxyetbyl-amino)carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline, 4-[(3-chloro-4-nuoro-phenyl)amino]-6-(l-ethyl-piperidin-4-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-nuc)ro-phenyl)amino|-6r(cis-4-(N-methanesulphonyl-N-methyl-amino)-cyclohexan-l-yloxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[cis-4-(N-acetyl-N-methyl-amino)-cyclohexan-l-yloxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-methylamino-cyclohexan-l-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[trans-4-(N-niethanesulphonyl-N-methyl-amino)-cyclohexan-l-yloxy]-7-methoxy-quinazoline, 4- (3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-dimethylamino-cyclohexan-l-yloxy)-7-mcthoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4- {N-[(morpholin-4-yl)carbonyl]-N-methyl-amino} -cyclohexan- l-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[2-(2,2-dimethyl-6-oxo-morpholin-4-yl)-ethoxy]-7-[(S)-(letrahydrofuran-2-yl)methoxy]-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(l-methanesulphonyl-piperidin-4-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(l-cyano-piperidin-4-yloxy)-7-methoxy-quinazoline, and 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{ l-[(2-methoxyethyl)carbonyl]-piperidin-4-yloxy}-7-niethoxy-quinazoline, optionally in the form of the racemates, enantiomers or diastereomers thereof, optionally in the form of the pharmacologically acceptable acid addition salts thereof, the solvates and/or hydrates thereof.<br>
By acid addition salts with pharmacologically acceptable acids which the compounds may be capable of forming are meant, for example, salts selected from among the hydrochloride,<br><br>
hydrobromide, hydroiodide, hydrosulphate, hydrophosphate, hydromethanesulphonate, hydronitrate, hydrornaleate, hydroacetate, hydrobenzoate, hydrocitrate, hydrofumarate, hydrotartrate, hydrooxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulphonate, preferably the hydrochloride, hydrobromide, hydrosulphate, hydrophosphate, hydrofumarate and hydromethanesulphonate.<br>
Examples of antiallergics are: disodium cromoglyeate, nedocromil. Examples of ergot alkaloids arc: dihydroergotamine, ergotamine.<br>
Examples of substances suitable for inhalation include pharmaceutical compositions containing the above-mentioned active substances, and the salts and esters thereof and combinations of these active substances, salts and esters thereof.<br>
The proportion of suspended drug in the finished preparation is between 0.001 and 5 %, preferably 0.005 to 3 %, particularly 0.01 to 2 %. Surface-active substances are added in amounts of from 0.01 to 10 %, preferably 0.05 to 5 %, particularly 0.05 to 3 % (% = percent by weight).<br>
In the case of ipratropium bromide monohydrate the suspensions according to the invention preferably contain between 0.001 to 1%, particularly 0.005 to 0.5% ipratropium. Particularly preferred according to the invention are suspensions which contain 0.01 to 0.1% ipratropium.<br>
In the case of salbutamol and the salts thereof the suspensions according to the invention preferably contain between 0.005 to 5%, particularly 0.025 to 2.5% salbutamol. Particularly preferred according to the invention are suspensions which contain 0.05 to 1% salbutamol.<br>
In the case of tiotropium bromide monohydrate the suspensions according to the invention preferably contain between 0.001 to 1%, particularly 0.0012 to 0,8% tiotropium. Preferred according to the invention are suspensions which contain 0.002 to 0.5%, particularly preferably 0.008 to 0.4% tiotropium.<br>
By all the active substances, e.g. tiotropium or ipratropium, is meant in each case the free ammonium cation.   The propellant gas suspensions according to the invention are characterised in that they contain tiotropium or ipratropium in the form of the crystalline monohydrates. Accordingly, the present invention preferably relates to suspensions which contain crystalline tiotropium bromide monohydrate or ipratropium bromide monohydrate.<br><br>
With regard to tiotropium bromide monohydrate suspensions which contain 0.001 to 0.62%, particularly preferably 0.002 to 0.5, most particularly preferably 0.002 to 0.06 of crystalline tiotropium bromide monohydrate are of particular interest.<br>
The percentage amounts specified within the scope of the present invention are always percent by mass. If amounts by mass for tiotropium are expressed as percent by mass, the corresponding values for the crystalline tiotropium bromide monohydrate which is preferably used within the scope of the present invention may be obtained by multiplying by the conversion factor 1.2495. The same applies to ipratopium.<br>
If anhydrous propellant gases are used, a small amount of water is added to them according to the invention. However, it is also possible according to the invention to use water-containing propellant gases, which should have a specific water content when used. This water which is added to or present in the finished suspension formulation is different from water which is chemically bound in one of the active substances or excipients. Within the scope of the present invention this non-ehemically bound water is also referred to as free water, to distinguish it from the water which is molecularly or chemically bound to the active substance.<br>
It has been found that the suspended particles of active substance change when the water content is too low. On the other hand it has been found that the particle sizes change if the water content is too high. The optimum water content may be determined individually for each substance. It has been found that the preferred amount of water in the propellant gas TG 227 ea or in mixtures of TG 227 ea with propellant gases selected from among propane, butane, pentane, dimethylether, CHC1F2, CH2F2, CP^CHs, isobutane, isopentane and neopentane, is generally 10 to 1000 ppm, particularly preferably 50 to 500 ppm, and most particularly preferably the amount of water is 100 to 450 ppm.<br>
In the case of formulations containing ipratropium bromide monohydrate with propellant gas TG 227 ea the most preferred water content of the formulation is between 20 and 500 ppm, and the water content is particularly between 50 and 350 ppm.<br>
In the case of tiotropium bromide monohydrate the preferred water content is comparable to that for ipratropium bromide monohydrate. The most preferred range is between 50 and 230 ppm.<br><br>
It has also been found that the preferred quantity of water in the propellant gas TG 134 a or in mixtures of TG 134 a with propellant gases from the group propane, butane, pentane, dimethylether, CHC1F2, Cpl2p2, CFaCP^isobutane, isopentane and neopentane is between 30 and 4000 ppm, particularly preferably between 150 and 2000 ppm and most particularly preferably between 350 and 1700 ppm.<br>
In the case of formulations containing ipratropium rnonohydrate with propellant gas TG 134 a the most preferred water content of the formulation is between 70 and 1800 ppm, and in particular the water content is between 180 and 1300 ppm.<br>
In the case of tiotropium monohydrate the preferred water content is similar to that for ipratropium bromide. The most preferred range is between 180 and 900 ppm.<br>
If mixtures of the propellant gases TG 134 a and TG 227 ea are used, the preferred water contents are obtained from the mixing ratio of the two propellant gases.<br>
According to the invention these amounts of water are added to the propellant gases or to the finished aerosol suspensions if the propellant gas, propellant gas mixture or the formulation docs not contain any water (free water) in addition to the water chemically bound to the active substance. In the process, the water may have already been added to the propellant gas before the pharmaceutical suspension is prepared, or the pharmaceutical suspension may be prepared first with anhydrous propellant gas or propellant gas mixture and then the corresponding amount of water is added. The amounts given in ppm are based on the liquefied propellant as the reference magnitude.<br>
Within the scope of the present invention the term suspension formulation may be used instead of the term suspension. The two terms are to be regarded as equivalent within the<br>
scope of the present invention.<br>
The propellant-containing inhalable aerosols or suspension formulations according to the invention may also contain other constituents such as surface-active agents (surfactants), adjuvants, antioxidants or flavourings.<br>
The surface-active agents (surfactants) optionally present in the suspensions according to the invention are preferably selected from the group consisting of Polysorbate 20, Polysorbate 80, Myvacet 9-45. Myvacet 9-08. isopropyl myristate, oleic acid, propyleneglycol, polyethyleneglycoL Brij, ethyl oleate, glyceryl trioleate, glyceryl monolaurate, glyceryl<br><br>
monooleate, glyceryl monostearate, glyceryl monoricinoleate, cetylalcohol, oleyl oleate, sterylalcohol, cetylpyridinium chloride, block polymers, natural oil, ethanol and isopropanol. Of the above-mentioned suspension adjuvants Polysorbate 20, Polysorbate 80, Myvacet 9-45, Myvacet 9-08 or isopropyl myristate are preferably used. Myvacet 9-45 or isopropyl myristate are most preferably used.<br>
If the suspensions according to the invention contain surfactants these are preferably used in an amount of 0.0005 - 1 %, particularly preferably 0.005 - 0.5 %.<br>
The adjuvants optionally contained in the suspensions according to the invention are preferably selected from the group consisting of alanine, albumin, ascorbic acid, aspartame, betaine, cysteine, phosphoric acid, nitric acid, hydrochloric acid, sulphuric acid and citric acid. Ascorbic acid, phosphoric acid, hydrochloric acid or citric acid are preferably used, while hydrochloric acid or citric acid is most preferably used.<br>
Jf adjuvants are present in the suspensions according to the invention, these are preferably used in an amount of 0.0001-1.0 %, preferably 0.0005-0.1 %, particularly preferably 0.001-0.01 %, while an amount off).001-0.005 % is particularly important according to the invention.<br>
The antioxidants optionally contained in the suspensions according to the invention are preferably selected from the group consisting of ascorbic acid, citric acid, sodium edetate, editic acid, tocopherols, butylhydroxytoluene, butylhydroxyanisol and ascorbylpalmitate, while tocopherols, butylhydroxytoluene, butylhydroxyanisol or ascorbylpalmitate are<br>
preferably used.<br>
The flavourings optionally contained in the suspensions according to the invention are preferably selected from the group consisting of peppermint, saccharine, Dentomint®, aspartame and ethereal oils (for example cinnamon, aniseed, menthol, camphor), of which peppermint or Dentomint*) are particularly preferred.<br>
With a view to administration by inhalation it is essential to provide the active substances in finely divided form. For this purpose, the active substance is obtained in finely divided form either by grinding (micronising) or using other methods known in the prior art (e.g. precipitation, spray-drying). Methods of micronising active substances are known in the art. Preferably alter micronising the active substance has a mean particle size of 0.5 to lOum, preferably 1 to 6um, particularly preferably 1.5 to Sum. Preferably at least 50%, preferably at<br><br>
least 60%, particularly preferably at least 70% of the particles of active substance have a particle size which is within the size ranges mentioned above. Particularly preferably at least 80%, most preferably at least 90% of the particles of active substance have a particle size which is within the size ranges mentioned above.<br>
Surprisingly it has been found that suspensions may also be prepared which contain, in addition to the above-mentioned propellant: gases, only the active substance or active substances and no other additives. Accordingly, in another aspect, the present invention relates to suspensions which contain only the active substance or active substances and no other additives.<br>
The suspensions according to the invention may be prepared using methods known in the art. For this, the constituents of the formulation are mixed with the propellent gas or gases (optionally at low temperatures) and filled into suitable containers.<br>
The above-mentioned propellant-containmg suspensions according to the invention may be administered using inhalers known in the art (pMDIs = pressurized metered dose inhalers). Accordingly, in another aspect, the present invention relates to pharmaceutical compositions in the form of suspensions as hereinbefore described combined with one or more inhalers suitable for administering these suspensions. Moreover the present invention relates to inhalers, characterised in that they contain the propellant-containing suspensions according to the invention described hereinbefore.<br>
The present invention also relates to containers (e.g. cartridges) which are fitted with a suitable valve adjusted before use with regard to the water content. The containers may be used in a suitable inhaler and contain one of the above-mentioned propellant-containing suspensions according to the invention. Suitable containers (e.g. cartridges) and processes for filling these cartridges with the propellant-containing suspensions according to the invention are known in the art.<br>
In view of the pharmaceutical activity of anticholinergics the present invention also relates to the use of the suspensions according to the invention for preparing a pharmaceutical composition for inhalation or nasal administration, preferably for preparing a pharmaceutical composition for inhalative or nasal treatment of diseases in which anticholinergics may develop a therapeutic benefit.<br><br>
Particularly preferably the present invention also relates to the use of the suspensions according to the invention for preparing a pharmaceutical composition for the inhalative treatment of respiratory complaints, preferably asthma or COPD, mucoviscidosis, cystic fibrosis; and also systemic complaints, such as pain, migraine, high blood pressure, erectile disorders.<br>
The Examples that follow serve to illustrate the present invention in more detail, by way of example, without restricting it to their contents.<br>
Examples of formulations<br>
_L<br>
-	Ipratropium bromide monohydrate	0.03 wt.%<br>
-	Fenoterol hydrobromide	0.07 wt.%<br>
-	Myvacet type 9-08 (acetylated monoglyceride)	0.4 wt.%<br>
-	TG 227ea	99.5 wt.%<br>
Total	100 wt.% (15.9 g)<br>
-	Ipratropium bromide monohydrate	0.03 wt.%<br>
-	Fenoterol hydrobromide	0.07 wt.%<br>
-	Isopropylmyristatc	0.4 wt.%<br>
-	TG 221 ca	99.5 wt.%<br>
Total	100 wt.% (15.9 g)<br>
-	Ipratropium bromide monohydrate	0.03 wt.%<br>
-	Fenoterol hydrobromide	0.07 wt.%<br>
-	Tween 20	0.4 wt.%<br>
-	TG 221 ea	99.5 wt.%<br>
Total	100 wt.% (15.9 g)<br><br>
4,<br>
-	Ipratropium bromide monohydrate	0.03 wt.%<br>
-	Fenoterol hydrobroraide	0.07 wt.%<br>
-	Tween 80	0.4 wt.%<br>
-	TG 227ea	99.5 wt.%<br>
Total	100 wt.% (15.9 g)<br>
-	Ipratropium bromide monohydrate	0.03 wt.%<br>
-	Fenoterol hydrobrornide	0.07 wt.%<br>
-	Isopropylmyristatc	10. 00 wt.%<br>
-	TG 227 ea	89.90 wt.%<br>
Total	100 wt.% (15.9 g)<br><br>
-	Jpratropiurn bromide monohydrate	0.03 wt.%<br>
-	Fenoterol hydrobrornide	0.07 wt.%<br>
-	Isopropylmyristatc	10.00 wt.%<br>
-	Soyalecithin	0.004 wt.%<br>
-	TG 227en	89.9 wt.%<br>
Total	100 wt.% (15.9 g)<br>
r<br>
-	Ipratropium bromide monohydrate	0.03 wt.%<br>
-	Salbutarnol sulphate	0.19 wt.%<br>
-	Tween 20	0.4 wt.%<br>
-TG227ea	99.38 wt.%<br>
Total	100 wt.% (15.9 g)<br>
8,<br>
-	Ipratropium bromide monohydrate	0.03 wt.%<br>
-	Salbutamol sulphate	0.19 wt.%<br>
-	TG 227ea	99.78 wt.%<br>
Total	100 wt.% (15.9 g)<br>
Formulation examples 1 to 8 preferably contain between 50 and 300 ppm water.<br><br>
9,<br>
-	Ipratropium bromide monohydrate	0.04 wt.%<br>
-	Salbutamol sulphate	0.21 wt.%<br>
-TGl34a	99.75 wt.%<br>
Total	100 wt.% (14.8 g)<br>
Fonnulation example 9 may contain between 200 and 1000 ppm water.<br><br><br>
Patent Claims<br>
1)   Propellent-containing aerosol suspension containing particles of active substance with chemically bound water, at least 85 wt.% of a propellant gas or a propellant gas mixture with TG 227 ea and/or TG 134 a or in admixture with at least one other propellant gas selected from among propane, butane, pentane, dimethylether, CHC1F2, CH2F2, CFsCHs, isobutane, isopentane and neopentane, characterised in that the aerosol suspension contains additional free water in addition to the water chemically bound to the active substance.<br>
2)	Aerosol suspension according to claim 1, characterised in that it contains crystalline<br>
particles of active substance which bind the water as water of crystallisation, hydrate or<br>
complex,<br>
3)	Aerosol suspension according to claim 1 or 2, characterised in that the active substance<br>
selected from among the betamimetics, anticholinergics, steroids, antiallergics,<br>
derivatives of ergot alkaloids, triptanes, CGRP-antagonists, phosphodiesterase-V<br>
inhibitors, phosphodiesterase-IV inhibitors, LTD4-antagonists, EGFR-kinase inhibitors,<br>
and combinations of such active substances.<br>
4)	Aerosol suspension according to claim 3, characterised in that the suspension contains an<br>
anticholinergic as active substance, preferably ipratropium salt or tiotropium salt, more<br>
preferably ipratropium bromide or tiotropium bromide, particularly preferably<br>
ipratropium bromide monohydrate or tiotropium bromide monohydrate.<br>
5)	Aerosol suspension according to one of the preceding claims, characterised in that the<br>
amount of active substance is between 0.001 and 5 %, preferably 0.002 to<br>
3 %, particularly 0.002 to 2 %.<br>
6)	Aerosolsuspension according to one of the preceding claims, characterised in that, for the<br>
propellant gas 227 ea or mixtures with this propellant gas, the amount of water is between<br>
1 0 and 1000 ppm, particularly preferably between 50 and 500 ppm and most particularly<br>
preferably between 100 and 450 ppm.<br>
7)	Aerosol supension according to one of the preceding claims, characterised in that, for the<br>
propellant gas 1 34 a or mixtures with this propellant gas, the amount of water is between<br><br>
30 and 4000 ppm, particularly preferably between 150 and 2000 ppm and most particularly preferably between 350 and 1700 ppm.<br>
8)	Aerosol suspension according to one of the preceding claims, characterised in that it<br>
contains as further ingredients surface-active substances (surfactants), adjuvants,<br>
antioxidants and/or flavourings.<br>
9)	Aerosol suspension according to one of the preceding claims, characterised in that it<br>
contains as surface-active substances (surfactants) one or more compounds selected from<br>
among Polysorbate 20, Polysorbate 80, Myvacet 9-45, Myvacet 9-08, isopropyl<br>
myristate, oleic acid, propyleneglycol, polyethyleneglycol, Brij, ethyl oleate, glyceryl<br>
trioleate, glyceryl monolaurate, glyceryl monooleate, glyceryl monostearate, glyceryl<br>
monoricinoleate, cetylaleohol, oleyloleate, sterylalcohol, cetylpyridinium chloride, block<br>
polymers, natural oil, ethanol and isopropanol<br>
10)	Aerosol suspension according to one of the preceding claims, characterised in that it<br>
contains as adjuvants one or more compounds selected from among alanine, albumin,<br>
ascorbic acid, aspartame, betaine, cysteine, phosphoric acid, nitric acid, hydrochloric<br>
acid, sulphuric acid and citric acid.<br>
11)	Aerosol suspension according to one of the preceding claims, characterised in that it<br>
contains as antioxidants one or more compounds selected from among ascorbic acid,<br>
citric acid, sodium edetate, editic acid, tocopherols, butylhydroxytoluene,<br>
butylhydroxyanisol and ascorbylpalmitate.<br>
12)	Aerosol suspension according to one of the preceding claims, characterised in that it<br>
contains no other ingredients in addition to the active substance, water and the propellant<br>
gas or gases.<br>
13)	Use of an aerosol suspension according to one of claims 1 to 12 for preparing a<br>
pharmaceutical composition, preferably for preparing a pharmaceutical composition for<br>
the treatment, by inhalation or optionally by nasal route, of diseases in which<br>
anticholincrgics may confer a therapeutic benefit.<br>
14)	Use according to claim 1 3, characterised in that the diseases are respiratory complaints,<br>
preferably asthma, COPD, mucoviscidosis or cystic fibrosis.<br><br>
15)	Use according to one or more of claims 1-13, characterised in that the disease is a<br>
systemic complaint, preferably pain, migraine, hypertension or erectile disorder.<br>
16)	Process for preparing aerosol suspensions according to one of claims 1 to 12,<br>
characterised in that water-containing propellant gas or propellant gas mixture is used to<br>
prepare the aerosol suspension.<br>
1 7} Process for preparing aerosol suspensions according to one of claims 1 to 12,<br>
characterised in that an aerosol suspension is prepared with anhydrous propellant gas or propellant gas mixture and then water is added.<br>
18) Container for filling with a propellant-containing aerosol according to one or more of claims 1-12, characterised in that the container contains a suitable valve which is adjusted before use in relation to its water content.<br><br></td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NzYzOC1kZWxucC0yMDA2LUFic3RyYWN0ICgwOC0xMS0yMDEyKS5wZGY=" target="_blank" style="word-wrap:break-word;">7638-delnp-2006-Abstract (08-11-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NzYzOC1kZWxucC0yMDA2LWFic3RyYWN0LnBkZg==" target="_blank" style="word-wrap:break-word;">7638-delnp-2006-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NzYzOC1kZWxucC0yMDA2LUNsYWltcyAoMDgtMTEtMjAxMikucGRm" target="_blank" style="word-wrap:break-word;">7638-delnp-2006-Claims (08-11-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NzYzOC1kZWxucC0yMDA2LWNsYWltcy5wZGY=" target="_blank" style="word-wrap:break-word;">7638-delnp-2006-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NzYzOC1kZWxucC0yMDA2LUNvcnJlc3BvbmRlbmNlIE90aGVycy0oMjQtMDctMjAxMikucGRm" target="_blank" style="word-wrap:break-word;">7638-delnp-2006-Correspondence Others-(24-07-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NzYzOC1kZWxucC0yMDA2LUNvcnJlc3BvbmRlbmNlLW90aGVycyAoMDgtMTEtMjAxMikucGRm" target="_blank" style="word-wrap:break-word;">7638-delnp-2006-Correspondence-others (08-11-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NzYzOC1kZWxucC0yMDA2LUNvcnJlc3BvbmRlbmNlLU90aGVycy0oMDMtMDMtMjAxNCkucGRm" target="_blank" style="word-wrap:break-word;">7638-delnp-2006-Correspondence-Others-(03-03-2014).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NzYzOC1kZWxucC0yMDA2LUNvcnJlc3BvbmRlbmNlLU90aGVycy0oMjItMDEtMjAxMykucGRm" target="_blank" style="word-wrap:break-word;">7638-delnp-2006-Correspondence-Others-(22-01-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NzYzOC1kZWxucC0yMDA2LWNvcnJlc3BvbmRlbmNlLW90aGVycy5wZGY=" target="_blank" style="word-wrap:break-word;">7638-delnp-2006-correspondence-others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NzYzOC1kZWxucC0yMDA2LWRlc2NyaXB0aW9uIChjb21wbGV0ZSkucGRm" target="_blank" style="word-wrap:break-word;">7638-delnp-2006-description (complete).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NzYzOC1kZWxucC0yMDA2LWZvcm0tMS5wZGY=" target="_blank" style="word-wrap:break-word;">7638-delnp-2006-form-1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NzYzOC1kZWxucC0yMDA2LUZvcm0tMTgtKDI3LTA2LTIwMDgpLnBkZg==" target="_blank" style="word-wrap:break-word;">7638-delnp-2006-Form-18-(27-06-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NzYzOC1kZWxucC0yMDA2LWZvcm0tMi5wZGY=" target="_blank" style="word-wrap:break-word;">7638-delnp-2006-form-2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NzYzOC1kZWxucC0yMDA2LUZvcm0tMy0oMDMtMDMtMjAxNCkucGRm" target="_blank" style="word-wrap:break-word;">7638-delnp-2006-Form-3-(03-03-2014).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NzYzOC1kZWxucC0yMDA2LUZvcm0tMy0oMjQtMDctMjAxMikucGRm" target="_blank" style="word-wrap:break-word;">7638-delnp-2006-Form-3-(24-07-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NzYzOC1ERUxOUC0yMDA2LUZvcm0tMy5wZGY=" target="_blank" style="word-wrap:break-word;">7638-DELNP-2006-Form-3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NzYzOC1kZWxucC0yMDA2LWZvcm0tNS5wZGY=" target="_blank" style="word-wrap:break-word;">7638-delnp-2006-form-5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NzYzOC1kZWxucC0yMDA2LUdQQSAoMDgtMTEtMjAxMikucGRm" target="_blank" style="word-wrap:break-word;">7638-delnp-2006-GPA (08-11-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NzYzOC1kZWxucC0yMDA2LWdwYS5wZGY=" target="_blank" style="word-wrap:break-word;">7638-delnp-2006-gpa.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NzYzOC1kZWxucC0yMDA2LXBjdC0xMDUucGRm" target="_blank" style="word-wrap:break-word;">7638-delnp-2006-pct-105.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NzYzOC1kZWxucC0yMDA2LXBjdC0zMDEucGRm" target="_blank" style="word-wrap:break-word;">7638-delnp-2006-pct-301.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NzYzOC1kZWxucC0yMDA2LXBjdC0zMDQucGRm" target="_blank" style="word-wrap:break-word;">7638-delnp-2006-pct-304.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NzYzOC1kZWxucC0yMDA2LVBldGl0aW9uLTEzNyAoMDgtMTEtMjAxMikucGRm" target="_blank" style="word-wrap:break-word;">7638-delnp-2006-Petition-137 (08-11-2012).pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="259281-a-comunication-network-for-on-demand-guaranteed-bandwidth-service-for-internet-access-points.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="259283-an-improved-multi-speed-transmission.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>259282</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>7638/DELNP/2006</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>10/2014</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>07-Mar-2014</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>05-Mar-2014</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>18-Dec-2006</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>BOEHRINGER INGELHEIM INTERNATIONAL GMBH</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>BINGER STRASSE 173, 55216 INGELHEIM, GERMANY,</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>CHRISTEL SCHMELZER</td>
											<td>WELFENSTRASSE 14, 55218 INGELHEIM, GERMANY;</td>
										</tr>
										<tr>
											<td>2</td>
											<td>ARNE FROEMDER</td>
											<td>GRUNDSTRASSE 72, 55218 INGELHEIM,GERMANY</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>A61K 9/12</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/EP2005/006865</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2005-06-25</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>10 2004 032 322.4</td>
									<td>2004-07-02</td>
								    <td>Germany</td>
								</tr>
								<tr>
									<td>2</td>
									<td>10 2005 023 334.1</td>
									<td>2005-05-17</td>
								    <td>Germany</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/259282-aerosol-suspension-formulations-containing-tg-227-ea-or-tg-134-a-as-a-propellant by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 02:35:30 GMT -->
</html>
